Capricor Therapeutics is trading 5.43% down at $8.89 after a securities-fraud class-action lawsuit announcement on September 8, 2026. Broader markets are mixed, leaving company-specific legal and regulatory overhang as the clearest catalyst.
- Lead-plaintiff deadline: September 28, 2026
- Complaint alleges misleading statements and undisclosed changes to Deramiocel’s clinical-data analysis and statistical-analysis plan
- FDA concerns disclosed in July questioned the therapy’s effectiveness evidence; shares previously collapsed 64% after those disclosures